RBC Downgrades Merck to Sector Perform Despite Melanoma Trial Win, Cites $150 Valuation Amid 2028 Keytruda Patent Expiration
RBC Capital analyst Trung Huynh downgraded Merck (MRK) to 'Sector Perform' from 'Outperform' today, raising the price target to $150 from $142, according to reports. While describing the Phase 3 melanoma trial results as exceeding expectations, Huynh flagged the stock's $150 valuation as
MRK-0.98%
GateNews·4h ago
